CEO received an award of 6,200 WST derivative securities | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Sep 8, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Sep 10, 2026
CEOGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001518973-26-000007
- Filed / recorded
Sep 10, 2026, 7:40 PM UTCAdded to OQROOct 2, 2026, 12:29 PM UTC Data qualityVerified: identifiers matched exactly IssuerWEST PHARMACEUTICAL SERVICES INC Reporting personMichel Lagarde RelationshipDirector, Officer Officer titlePresident and CEO TableDerivative (Table II) Transaction dateSep 8, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- Each restricted stock unit represents a contingent right to receive one share of WST common stock.
- This award vests in four equal annual installments beginning on September 8, 2027.
Around the same time
Compensation award — excluded from discretionary-purchase analysis.
Derivative exercise or conversion — not an open-market buy.
West Pharmaceutical Services's Sr. VP & Chief HR Officer sold $863K of West Pharmaceutical Services shares. Nobody planned it ahead of time.